Pasithea Therapeutics Corp. (NASDAQ:KTTA – Get Free Report) was the target of a large growth in short interest in the month of September. As of September 30th, there was short interest totalling 171,300 shares, a growth of 42,725.0% from the September 15th total of 400 shares. Currently, 21.4% of the company’s shares are short sold. Based on an average trading volume of 916,900 shares, the short-interest ratio is currently 0.2 days.
Pasithea Therapeutics Price Performance
Shares of NASDAQ KTTA opened at $4.87 on Thursday. The business’s 50 day moving average is $4.71 and its two-hundred day moving average is $5.73. Pasithea Therapeutics has a 52-week low of $3.61 and a 52-week high of $17.40.
Pasithea Therapeutics (NASDAQ:KTTA – Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($3.71) earnings per share (EPS) for the quarter.
Pasithea Therapeutics Company Profile
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.
Recommended Stories
- Five stocks we like better than Pasithea Therapeutics
- Upcoming IPO Stock Lockup Period, Explained
- Carnival Has Analysts Going Wild: Here’s Why
- What is the Shanghai Stock Exchange Composite Index?
- Top Income Stocks Offering Big Dividend Yields and Future Growth
- What Investors Need to Know About Upcoming IPOs
- At $43 is it Time to Take Profit with Palantir?
Receive News & Ratings for Pasithea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pasithea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
